Novartis’ biotech shopping spree stays focused on the low-budget specials of the day
Novartis inked a string of acquisitions in the fourth quarter, but they barely registered on the Big Pharma Richter scale for M&A. There was a deal worth up to $665 million for Oklahoma City-based Selexys. The UK’s Ziarco was swallowed whole after shopping itself for around a billion dollars. A deal for Encore Vision in Fort Worth wound up the year.
Small, low profile companies. Small deals. Little or no details on the numbers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.